Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 18;19:99. doi: 10.1186/s13075-017-1316-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — a Event-free time, proportion of patients without new vascular lesions on different treatment. TNF inhibitor treatment included either infliximab (27 patients) or etanercept (5 patients) +/- disease-modifying antirheumatic drugs (DMARDs) and prednisolone. DMARD treatment included methotrexate or azathioprine + prednisolone, total 40 patients. Prednisolone monotherapy, 15 patients. *Comparison of the proportion of patients event-free in different treatment arms (chi-square test) after 5 years follow up. b Disease activity at the last visit. NIH (National Institutes of Health) disease activity score